Puma Biotechnology (PBYI) Competitors $2.75 -0.03 (-1.08%) (As of 12/20/2024 05:31 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends PBYI vs. TERN, TRML, VECT, PHAT, PROK, ATXS, DNA, ANNX, HUMA, and PRTCShould you be buying Puma Biotechnology stock or one of its competitors? The main competitors of Puma Biotechnology include Terns Pharmaceuticals (TERN), Tourmaline Bio (TRML), VectivBio (VECT), Phathom Pharmaceuticals (PHAT), ProKidney (PROK), Astria Therapeutics (ATXS), Ginkgo Bioworks (DNA), Annexon (ANNX), Humacyte (HUMA), and PureTech Health (PRTC). These companies are all part of the "pharmaceutical products" industry. Puma Biotechnology vs. Terns Pharmaceuticals Tourmaline Bio VectivBio Phathom Pharmaceuticals ProKidney Astria Therapeutics Ginkgo Bioworks Annexon Humacyte PureTech Health Puma Biotechnology (NASDAQ:PBYI) and Terns Pharmaceuticals (NASDAQ:TERN) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, community ranking, risk, profitability, valuation, dividends, institutional ownership, earnings and media sentiment. Which has more volatility & risk, PBYI or TERN? Puma Biotechnology has a beta of 1.08, meaning that its stock price is 8% more volatile than the S&P 500. Comparatively, Terns Pharmaceuticals has a beta of -0.36, meaning that its stock price is 136% less volatile than the S&P 500. Which has higher earnings and valuation, PBYI or TERN? Puma Biotechnology has higher revenue and earnings than Terns Pharmaceuticals. Terns Pharmaceuticals is trading at a lower price-to-earnings ratio than Puma Biotechnology, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPuma Biotechnology$243.57M0.55$21.59M$0.485.73Terns Pharmaceuticals$1M497.74-$90.21M-$1.18-4.97 Is PBYI or TERN more profitable? Puma Biotechnology has a net margin of 9.56% compared to Terns Pharmaceuticals' net margin of 0.00%. Puma Biotechnology's return on equity of 41.60% beat Terns Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Puma Biotechnology9.56% 41.60% 10.71% Terns Pharmaceuticals N/A -32.76%-31.33% Do insiders & institutionals believe in PBYI or TERN? 61.3% of Puma Biotechnology shares are held by institutional investors. Comparatively, 98.3% of Terns Pharmaceuticals shares are held by institutional investors. 23.7% of Puma Biotechnology shares are held by company insiders. Comparatively, 15.1% of Terns Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Does the MarketBeat Community believe in PBYI or TERN? Puma Biotechnology received 508 more outperform votes than Terns Pharmaceuticals when rated by MarketBeat users. Likewise, 67.07% of users gave Puma Biotechnology an outperform vote while only 60.87% of users gave Terns Pharmaceuticals an outperform vote. CompanyUnderperformOutperformPuma BiotechnologyOutperform Votes55067.07% Underperform Votes27032.93% Terns PharmaceuticalsOutperform Votes4260.87% Underperform Votes2739.13% Do analysts prefer PBYI or TERN? Puma Biotechnology currently has a consensus price target of $7.00, indicating a potential upside of 154.55%. Terns Pharmaceuticals has a consensus price target of $18.30, indicating a potential upside of 212.29%. Given Terns Pharmaceuticals' higher probable upside, analysts plainly believe Terns Pharmaceuticals is more favorable than Puma Biotechnology.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Puma Biotechnology 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Terns Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.80 Does the media prefer PBYI or TERN? In the previous week, Terns Pharmaceuticals had 2 more articles in the media than Puma Biotechnology. MarketBeat recorded 3 mentions for Terns Pharmaceuticals and 1 mentions for Puma Biotechnology. Puma Biotechnology's average media sentiment score of 1.45 beat Terns Pharmaceuticals' score of 1.38 indicating that Puma Biotechnology is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Puma Biotechnology 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Terns Pharmaceuticals 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryPuma Biotechnology beats Terns Pharmaceuticals on 13 of the 18 factors compared between the two stocks. Ad Crypto Swap ProfitsURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happens like clockwork every 4 years, during the December to February window of a Bitcoin halving year. This is where fortunes are made – often LITERALLY overnight.>> Register for the Workshop Now Get Puma Biotechnology News Delivered to You Automatically Sign up to receive the latest news and ratings for PBYI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PBYI vs. The Competition Export to ExcelMetricPuma BiotechnologyPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$134.99M$6.57B$5.07B$9.08BDividend YieldN/A2.97%4.87%4.21%P/E Ratio5.7310.5999.0517.15Price / Sales0.55195.041,121.17116.80Price / Cash4.1457.1641.5237.88Price / Book2.465.104.754.78Net Income$21.59M$151.51M$119.33M$225.60M7 Day Performance-4.51%-2.13%-1.86%-1.23%1 Month Performance-5.50%-3.14%11.40%3.07%1 Year Performance-30.20%11.53%30.26%16.48% Puma Biotechnology Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PBYIPuma Biotechnology3.9383 of 5 stars$2.75-1.1%$7.00+154.5%-30.0%$134.99M$243.57M5.73185Positive NewsTERNTerns Pharmaceuticals4.2382 of 5 stars$6.95+3.3%$18.30+163.3%-6.8%$590.33M$1M-5.7040TRMLTourmaline Bio2.44 of 5 stars$22.39+2.7%$54.00+141.2%+8.7%$574.15MN/A-7.7344VECTVectivBioN/A$16.85flatN/AN/A$573.24M$27.34M0.0030PHATPhathom Pharmaceuticals2.996 of 5 stars$8.35+5.8%$23.00+175.4%-9.3%$570.97M$680,000.00-1.48110PROKProKidney2.0358 of 5 stars$1.93+7.2%$4.50+133.8%-15.6%$561.45MN/A-3.553Gap DownATXSAstria Therapeutics2.0765 of 5 stars$9.71+2.0%$25.60+163.6%+58.0%$547.94MN/A-4.5630News CoveragePositive NewsDNAGinkgo Bioworks0.7475 of 5 stars$9.50+0.6%$4.58-51.8%N/A$546.06M$251.46M-0.721,218Positive NewsANNXAnnexon2.1152 of 5 stars$5.12+15.3%$15.80+208.6%+81.6%$545.76MN/A-4.9060Analyst ForecastNews CoverageHUMAHumacyte3.339 of 5 stars$4.23+3.2%$13.00+207.3%+69.3%$532.38M$1.57M-3.06150Analyst ForecastGap UpPRTCPureTech Health1.9926 of 5 stars$22.20+9.1%$45.00+102.7%+3.8%$531.51M$3.33M0.00100Gap DownHigh Trading Volume Related Companies and Tools Related Companies Terns Pharmaceuticals Competitors Tourmaline Bio Competitors VectivBio Competitors Phathom Pharmaceuticals Competitors ProKidney Competitors Astria Therapeutics Competitors Ginkgo Bioworks Competitors Annexon Competitors Humacyte Competitors PureTech Health Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:PBYI) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Puma Biotechnology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Puma Biotechnology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free PBYI Stock Alerts